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ABSTRACT
Chlordiazepoxide Increases Risky Choice
Devin Andrew Galdieri
Probability discounting is a measure of risky choice that is correlated with maladaptive behavior
and psychological disorders. Benzodiazepines are a class of drug on which relatively little riskychoice research has been conducted, particularly under conditions of chronic drug exposure.
Chlordiazepoxide, a standard benzodiazepine, was administered to rats that had been trained to
respond on a risky-choice task in which a choice was available between a single food pellet with
100% certainty or three food pellets with probabilities of delivery that decreased across each
experimental session. During baseline, responding was sensitive to the programmed
contingencies and larger-reinforcer choice decreased as the probability of delivery decreased.
Acute administration of chlordiazepoxide dose-dependently increased risky choice. Tolerance to
chlordiazepoxide’s effects on larger-reinforcer-choice was observed after chronic drug exposure.
The results of the present study indicate that acute chlordiazepoxide can increase risky choice in
a probability-discounting task and that tolerance to this effect develops after chronic exposure to
the drug. Limitations of the probability-discounting task and its relation to the hypothetical
construct “risky choice” are discussed, as are suggestions for additional pharmacological targets
and procedural variations for future studies on benzodiazepines, the GABA system, and risky
choice.
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Chlordiazepoxide Increases Risky Choice
Maladaptive decision-making, a component of many psychiatric disorders and
problematic behavior in general, can be divided into several categories. Risky choice is a
category of maladaptive decision-making that can be conceptualized as preference for a larger,
riskier reward over a smaller, certain reward. Risky choice can be measured using probabilitydiscounting procedures, which are supported by a broad literature base and can provide multiple
measures that describe how risky choice changes as a function of environmental influences. One
such environmental influence is pharmacological manipulation.
Many drugs have been shown to exert effects on risky choice in human and non-human
animals as measured by probability-discounting procedures. Benzodiazepines are a class of drugs
that have been shown to increase some forms of risky choice in humans and non-human animals,
but little is known about how benzodiazepines affect probability discounting in humans or nonhuman animals. Benzodiazepines produce numerous effects on decision-making when
administered acutely, and long-term use is associated with a similar but distinct set of effects.
The present study was designed to examine effects of acute and chronic administration of a
typical “gold-standard” benzodiazepine, chlordiazepoxide, in a well-established laboratory
model of risky choice (i.e., a probability-discounting procedure).
Risky Choice
Maladaptive decision-making is a key feature of numerous psychiatric disorders,
including attention-deficit/hyperactivity disorder (ADHD), gambling disorder, substance-use
disorders, mood disorders, and primary psychotic disorders (Berry et al., 2019; Drechsler et al.,
2010; Hart, Brown et al., 2019; Hayashi et al., 2018; Kyonka & Schutte, 2018; Moreira et al.,
2019; Shurman et al., 2005). Maladaptive decision-making is also associated with risky sexual
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practices, increased drug use, texting while driving, and other high-risk behavior (Chuang et al.,
2017; Dir et al., 2014; Hayashi et al., 2016). Contemporary accounts of maladaptive decisionmaking often discuss separate forms of maladaptive decision-making. Excessive devaluation of
delayed rewards (delay discounting) or suboptimal valuation of uncertain outcomes (probability
discounting) are two commonly discussed forms of maladaptive decision-making. When
maladaptive decision-making occurs in relation to uncertain outcomes, it is referred to as risky
choice.
Risky choice can be conceptualized as preference for a larger reward that is associated
with some probability of an adverse outcome instead of a smaller reward with no probability of
an adverse outcome. An adverse outcome may come in the form of a smaller reward, a lack of
reward altogether, a time-out from earning rewards, and/or the addition of an aversive stimulus.
For example, choosing to speed on the freeway in order to get to a destination quickly instead of
driving the speed limit and arriving later could be a risky choice. There is increased probability
of a receiving a speeding ticket when speeding (and subsequently arriving late), but also a greater
and more likely potential reward (e.g., less time spent driving, arriving sooner).
Often, it is advantageous to discount the value of an outcome when it is relatively
unlikely. For example, many people take the risk of driving on the freeway every day to get to
work because the risk of being involved in an automobile accident is relatively low, and the
rewards associated with going to work are relatively high. However, most people choose not to
speed on the freeway while heading to work. In this scenario, the potential to arrive at work a
few minutes early does not outweigh the potential consequences of a citation and/or collision.
In either case, risky choice can be related to risk aversion (some individuals may be less
sensitive to risks) and/or reward sensitivity (some individuals may be more sensitive to rewards).
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Consider, for example, an individual with a gambling problem who continues to spend money
even though it is extremely unlikely that such behavior will result in a net gain. Continued
gambling could be due to an insensitivity to loss, or to an oversensitivity to reward. On the other
hand, the individual could simply be ineffective at determining the relative value of probabilistic
outcomes (i.e., the economic utility of continued gambling), regardless of their sensitivity to
winning or losing. In an effort to study this phenomenon objectively, researchers have developed
several pre-clinical models to assess risky choice.
Risky choice can be assessed experimentally with several procedures. Pre-clinical models
include rat gambling tasks, the Balloon Analog Risk Task (BART), and probability-discounting
procedures (e.g., Cardinal & Howe, 2005; Hastjarjo et al., 1990; Jentsch et al., 2010; Winstanley
& Floresco, 2016; Zeeb et al., 2009). Rat gambling tasks typically involve a choice between
responses that produce varying amounts of reward but are also associated with differing
probabilities of non-reward in the form of time-out from earning rewards or no reward delivery.
Similarly, the BART involves a choice between two responses. However, in the BART, one
response increases the amount of reward available but also increases the likelihood that all of the
accrued rewards will be erased (the BART takes its name from a hypothetical task in which an
individual attempts to pump up a balloon as much as possible without popping it). The other
response option in the BART allows for a “cash out” where the previously accrued reward
amount is delivered. In essence, the BART involves the choice between a smaller reward with
less risk and a larger reward with an increasing risk of loss.
Probability-discounting procedures involve a choice between two responses as well.
Response options include a response that produces a smaller reward every time, and a response
that produces a larger reward with some probability of non-delivery. The probability of the larger
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reward being delivered is manipulated (typically reduced) across trials, and the relative value of
the larger reward is said to be discounted as a function of the probability of its non-delivery.
Probability-discounting procedures have several advantages over other measures of risky
choice. First, there is a robust literature base in which probability-discounting procedures have
been used to characterize group differences in risk-taking clinical subpopulations and healthy
controls (e.g., Drechsler et al., 2010; Kyonka & Schutte, 2018; Levy et al., 2019; Hart et al.,
2019). This literature also includes experimental data regarding various environmental and
pharmacological manipulations that alter probability discounting (e.g., Lane et al., 2008; Lane et
al., 2005; St. Onge, et al., 2010; St. Onge & Floresco, 2009). Second, probability-discounting
procedures with non-human animals typically require minimal pre-training and produce longlasting stability in responding, which allows for risky choice to be analyzed over time (Galdieri,
2018; Ozga & Anderson, 2018). Third, probability-discounting procedures share some features
with the similar yet distinct phenomenon of delay discounting. Identifying similarities and
differences in these distinct but related forms of maladaptive decision-making is a separate,
ongoing area of research (for a review of similarities and differences, see Green & Myerson,
2014). Finally, probability-discounting procedures produce several useful measures that allow
multiple levels of analysis of choice.
There are at least five measures that can be obtained with probability-discounting
procedures. Percent larger-reinforcer choice is the proportion of responses made for the larger,
risky reward overall and at a given probability of delivery. Plotting percent larger-reinforcer
choice as a function of decreasing probability of delivery yields a hyperboloid curve. Such a
curve can be analyzed qualitatively via visual inspection and quantitatively by calculating the
area under the curve (AUC). Indifference points (IPs) are calculated by interpolating the
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probability value at which responses for the larger, risky reward and the smaller, certain reward
are equally likely. Increased percent larger-reinforcer choice (specifically at low probabilities of
delivery), increased IPs, and increased AUC are all indicative of increased risky choice.
Trial-by-trial measures of responding can also be obtained by analyzing how responding
changes following a non-reinforced response for the larger reinforcer (lose-shift ratio; LSR) and
how responding persists following a reinforced response for the larger reinforcer (win-stay ratio;
WSR). LSRs and WSRs are important because they reflect how responding is affected by recent
extinction (lose-shift) and recent reinforcement (win-stay), and are differentially affected by
environmental factors (Bari et al., 2010; Forder & Dyson, 2016; Reed, 2018; Thapa & Gruber,
2018; Stopper & Floresco, 2011; Tom et al., 2007).
Pharmacological Manipulation of Risky Choice
One factor that affects risky choice in general is pharmacological manipulation. Drugs
that have been shown to increase risky choice in probability-discounting experiments include
dopaminergic drugs such as d-amphetamine and flupenthixol (e.g., St. Onge et al., 2010; St.
Onge & Floresco, 2009). Noradrenergic drugs, such as dexmedetomidine and clonidine have
been shown to reduce risky choice, while noradrenaline antagonists such as atomoxetine and
reboxetine have produced mixed results, with some studies reporting increases, and others
reporting no effect (Cui et al., 2018; Montes et al., 2015; Ozga & Anderson, 2018). Several
studies have found no effect of serotonergic manipulations on risky choice (Anderson, et al.,
2003; Blaes et al., 2018; Mobini et al., 2000; Yang et al., 2016).
There is some evidence that gamma-aminobutyric acid (GABA) receptors, which are
activated by ethanol and other drugs, play a role in risky choice. Results of some studies have
shown that acute and chronic ethanol exposure can increase risky choice in probability-
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discounting and other procedures (Bidwell et al., 2013; Schindler et al., 2014; Wallin-Miller et
al., 2017). However, little is known about how other pharmacological manipulations of the
GABA system affect risky choice.
Benzodiazepines and the GABA System
Benzodiazepines are a class of drugs that activate the GABA system. Benzodiazepines are
prescribed for short-term treatment of conditions such as anxiety, seizures, and alcohol
withdrawal (Kaiser Permanente, 2019). In 2017, more than one-in-eight adults reported using
benzodiazepines at least once, with misuse accounting for approximately 17% of all use (O’Neal,
2018). Between 2004 and 2010, emergency-department visits for benzodiazepine misuse
increased 139% (O’Neal). Admissions to benzodiazepine-abuse treatment programs nearly
tripled between 1998 and 2008, although admissions to drug-abuse treatment programs overall
increased by only 11% (Schmitz, 2016). Benzodiazepine overdose can include respiratory
depression, muscle and brain damage, and on rare occasions death (Gross, 1992). However, fatal
overdoses are most common when benzodiazepines are combined with other substances such as
alcohol or opioids (NIDA, 2018). In fact, over 30% of opioid overdoses also involved
benzodiazepines and 23% of fatal opioid overdoses involved benzodiazepines. Nevertheless, the
rate of benzodiazepines co-prescribed with opioids increased from nine to seventeen percent
between 2001 and 2013 (NIDA). Aside from the risk of overdose, benzodiazepine use is
associated with various forms of risky behavior.
Benzodiazepine use has been associated with robbery and weapons-related crimes,
increased likelihood of criminal behavior and memory loss in forensic psychiatric patients,
increased antisocial behavior in violent criminals, and increased likelihood of poly-drug use
(Daderman, 2005; Daderman & Edman, 2001; Daderman et al., 2002). Benzodiazepine use has
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also been associated with increased risk of automobile accidents, unintentional drowning, and
increased sexual disinhibition (Leung, 2011; Orriols et al., 2011; Pajunen et al., 2017; Simoes et
al., 2009, Van der Sluiszen et al., 2017). Because benzodiazepines act primarily on GABA
receptors, it is likely that these risk-increasing effects are mediated at least in part by the GABA
system.
The GABA system has been implicated in maladaptive decision-making in human and
non-human animals. Individuals with gambling disorders are more likely to have impaired
GABA transmission and individuals with higher levels of cerebrospinal-fluid GABA are more
impulsive than controls (Mick et al., 2017; Nordin & Sjodin, 2007). In non-human animals,
GABA dysregulation is associated with increased impulsivity and risk taking, and GABA
agonists have been shown to produce impulsive responding in rats in a reaction-time task and
increase choice for a larger reward that is associated with some probability of foot shock (Jupp et
al., 2013; Mitchell et al., 2011; Murphy et al., 2012; Paine et al., 2011). There is also some
evidence to suggest that individual differences in risk-taking may be related to differential
genetic expression of GABA receptors in certain brain regions (Ucha et al., 2019). GABA
agonists such as diazepam, alprazolam, and flunitrazepam have also been shown to affect risky
choice in humans.
Benzodiazepines and Risky Choice
Several benzodiazepines have been studied for their effects on risky choice with humans.
In one study, human subjects were given a range of doses of diazepam and tested on a battery of
assessments, including a risky decision-making task. Subjects were instructed to choose between
options with varying reward sizes and varying probabilities of delivery. Diazepam increased
risky choice at 20 mg which was the highest dose administered (Deakin et al., 2004).
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Alprazolam and flunitrazepam have also been shown to increase risky choice in risky
decision-making tasks with humans (Lane et al., 2005; 2008). Lane and colleagues (2005) found
that alprazolam administration dose-dependently increased risky choice in a computerized risktaking task. The computerized task required subjects to choose between a risky and a non-risky
choice by making 25 responses on a computer-screen button. The non-risky choice produced
$0.01 and the risky choice produced either a gain or loss of $0.25 - $1.00 with equal probability.
Lane and colleagues also administered flunitrazepam to human subjects in a separate
(2008) study using the same computerized task and found that flunitrazepam also dosedependently increased risky choice. Notably, these studies employed procedures that deviate
considerably from what may be considered “standard” pre-clinical models of risky choice,
making comparisons of risky choice across species and experimental settings difficult. Indeed,
little is known about how the performance of humans or non-human animals on probabilitydiscounting tasks is affected by benzodiazepines.
Benzodiazepines and Tolerance
Benzodiazepines are indicated for short-term (two to four weeks) relief of anxiety-related
symptoms, but are may also be prescribed for much longer periods of time (Kaiser Permanente,
2019). Recreational users and individuals who abuse benzodiazepines may also use them for
longer periods, with many individuals developing tolerance and dependence. However, little is
known about how repeated, chronic use affects decision-making. Similarly, little is known about
repeated exposure to benzodiazepines and the possible development of tolerance to their effects
on risky choice.
In general, tolerance to the various effects of benzodiazepines develops at different rates
and occurs due to changes in the quantity and function of GABA receptors rather than changes in

CHLORDIAZEPOXIDE INCREASES RISKY CHOICE

9

drug metabolism (Ferreri et al., 2015; Hutchinson et al., 1996) Some studies have shown that in
humans, tolerance to sedative effects develops in as little as 3 – 14 days (Johnson & Streltzer,
2013; Potts & Krishnan, 1992). In addition to tolerance, long-term use of benzodiazepines is
associated with cognitive impairments, increased risk for automobile accidents, increased risk of
hip fracture in elderly populations, sexual dysfunction, depression, disinhibition, and withdrawal
symptoms (Cohen & Rosenbaum, 1987; Ford & Law, 2014; Johnson & Streltzer; 2013). Despite
clinical and experimental evidence that benzodiazepine use, especially prolonged use, is
associated with numerous physiological and behavioral risks, little is known about how risky
choice is affected by short- or long-term benzodiazepine use.
Chlordiazepoxide
Chlordiazepoxide (CDP) is a low- to medium-potency benzodiazepine with a relatively long
half-life of 5 to 30 hours (Griffin et al., 2013). CDP is metabolized into desmethyldiazepam,
which has a longer half-life of 40-120 hours, and oxazepam, which has a shorter half-life of 5-15
hours (Griffin et al., 2013). CDP’s intermediate potency and long duration of action make it an
ideal compound for experimental studies that test a range of doses in relatively long experimental
sessions. CDP has been shown to produce numerous behavioral effects in rats, including
increased social behavior, impaired acquisition of novel behavior, increased punished
responding, increased aggression, and increased impulsivity (Bonuti & Morato, 2018; Carinal et
al., 2000; Evenden & Ko, 2005; Manzo et al., 2015; McMillan & Leander, 1978; Miczek &
Barry, 1977; Pitts et al., 2006).
Statement of the Problem
Risky choice is an important aspect of many forms of problematic behavior. Probabilitydiscounting procedures are well-established as an effective and efficient means of assessing risky
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choice. Benzodiazepines are a commonly prescribed class of drugs that are known to alter
decision-making, yet little is known about their effects on probability discounting. To date, no
experimental studies have analyzed how prolonged exposure to benzodiazepines affects
probability discounting, or how tolerance to acute or chronic effects develop over time.
Chlordiazepoxide is a benzodiazepine with a long duration of action that produces effects typical
of the benzodiazepine drug class. The present study assessed how risky choice in a probabilitydiscounting procedure is affected by acute and chronic exposure to chlordiazepoxide, as well as
how tolerance to any such effects develops.
Method
Overview
The experiment began with lever-press training in which food-pellets were initially
delivered on a continuous schedule of reinforcement (each response on either lever produced
food), and then on a probabilistic schedule of reinforcement (each response on either lever had a
50% chance of producing food). Next, a probability-discounting procedure was implemented in
which a choice between a single food pellet delivered with 100% probability or three food pellets
delivered with one of five probabilities (100%, 50%, 25%, 12.5%, 6.25%) was available. The
probability of the larger reinforcer being delivered decreased across blocks of trials within each
session, and sessions were conducted until stable responding was observed (e.g., St. Onge et al.,
2010).
Once stability was observed, rats were administered acute doses of CDP and tested using
the same probability-discounting procedure. The acute-exposure phase of the study allowed for
observation of how short-term exposure to CDP affected risky choice. Once all rats had received
each acute dose at least twice, chronic CDP exposure began. Chronic exposure consisted of daily
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injections of an intermediate dose (10.0 mg/kg) of CDP for a minimum of 30 days, depending on
stability of responding. Following chronic exposure, the procedure from the acute phase of the
study was repeated with the caveat that the chronic dose was administered every day that acute
doses were not. This replication of the acute phase of the study during chronic exposure allowed
for observation of how chronic exposure to CDP affected risky choice over time, as well as how
tolerance to risky-choice-altering effects of CDP developed.
Subjects
Eight experimentally naïve male Sprague-Dawley rats served as subjects during the acute
phase of the study. Two rats died due to unrelated health issues during the chronic-exposure
phase, leaving six rats for the remainder of the study. All rats were pair-housed in controlled
environmental conditions (temperature, 24°C; 12-h reverse light/dark cycle), with continuous
access to water in home cages. Sessions were conducted at approximately the same time each
day, five days per week (Monday-Friday). Rats were fed approximately 13 g of food
approximately 30 min following sessions, resulting in approximately 22 h of food restriction
prior to each experimental session.
Apparatus
Sessions were conducted in eight standard operant-conditioning chambers for rats, each
enclosed in a melamine sound-attenuating cubicle (Med Associates, VT). Each chamber
contained a working area of 30.5 cm by 24.5 cm by 21.0 cm, a grid floor, and a 45-mg pellet
dispenser with a pellet receptacle centered between two retractable response levers. Levers were
11.5 cm apart from each other and required at least 0.25 N of force for a response to be recorded.
Levers were 4.8 cm wide, protruded 1.9 cm into the chamber, and were elevated 8 cm from the
grid floor. Two 28-V stimulus lights, 2.5 cm in diameter, were approximately 7 cm above each
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lever. Each chamber had a 28-V houselight on the wall opposite to the working wall, and a
ventilation fan to circulate air and to mask extraneous noise. Data collection and programmed
consequences were controlled by a personal computer equipped with Med-PC software (Med
Associates, VT).
Drugs
Chlordiazepoxide hydrochloride (CDP, Sigma, St. Louis MO; 7-Chloro-2(methylamino)-5-phenyl-3H-1, 4-benzodiazepine 4-oxide hydrochloride) was dissolved in 0.9%
sodium-chloride solution on test days. Extra solution was stored in a refrigerator to prevent
hydrolysis (Vinkers et al., 2010). CDP and its vehicle control (saline) were administered at a
volume of 1 ml/kg intraperitoneally 15 minutes prior to the start of experimental sessions.
Dosing and preparation procedures were adapted from previous research with CDP and operant
behavior in rats (van Haaren & Anderson, 1998; van Haaren, Katon, & Anderson, 1997).
Procedure
Lever-press Training
At the beginning of each lever-press training session, both levers extended into the
chamber and food pellets were delivered on a conjoint variable-time (VT) 60 s fixed-ratio (FR) 1
schedule of reinforcement. On this schedule, a food pellet was delivered an average of once
every 60 s independent of responding, and immediately following any lever-press response.
Lever pressing did not affect delivery of pellets from the VT component of the schedule and each
of these sessions terminated following 60 food-pellet deliveries. If lever pressing had not been
acquired after five sessions, it was shaped by reinforcement of successive approximations. After
lever-press acquisition, an FR 1 schedule of reinforcement alternating between levers was
implemented. Alternating FR 1 sessions consisted of one lever extending into the chamber with a
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cue light illuminated over it. A response on this lever resulted in the delivery of a single food
pellet. The FR 1 contingency and cue light alternated between the left and right levers after every
five responses. Alternating FR 1 sessions continued until lever pressing was consistent on both
levers and each session terminated after the delivery of 40 food pellets.
Probabilistic-Reinforcement Training
After lever-press training was completed, probabilistic reinforcement training began
(adapted from Ozga & Anderson, 2018). These sessions consisted of 90 trials each, and trials
were presented every 40 s. Each trial consisted of a single, randomly determined lever being
extended into the chamber for 10 s, and a response on this lever produced a single food pellet
with 50% probability. Probabilistic-reinforcement training continued for a minimum of five
sessions, and until fewer than 10 trials were omitted across three consecutive sessions.
Probability-Discounting Procedure
The probability-discounting procedures used in this study were based on those described
in the work of Floresco et al. (2008). After probabilistic-reinforcement training was complete,
the probability-discounting procedure was in effect for the remainder of the study. During the
probability-discounting procedure, one lever was associated with a small/certain reinforcer and
the other with a large/risky reinforcer. The position of the lever associated with each reinforcer
was counterbalanced across rats and remained constant throughout the study. Each session began
with a 10-minute blackout period followed by five blocks of trials, with 16 forced-choice and
eight free-choice trials in each block. The probability of the large/risky reinforcer was 100% in
the first block, and then decreased across blocks (100%, 50%, 25%, 12.5%, and 6.25%).
In forced-choice trials, a single, randomly determined lever was inserted into the chamber
and a cue light was illuminated above the lever. A response on the lever produced either a
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small/certain reinforcer (one food pellet, 100% probability), or a large/risky reinforcer (three
food pellets, varying probability). Pellet delivery was signaled by flashes of the houselight, with
a single 0.1-s flash occurring as each pellet was delivered. Levers retracted and a 20-s inter-trial
interval (ITI) began as soon as the final food pellet was delivered at the end of each trial. To
ensure that responding was exposed to the probability assigned to the lever that produced the
large/risky reinforcer in each block, the probability of pellet delivery on each forced-choice trial
was selected from a pre-determined sampling distribution, such that responses on that lever
produced reinforcement on exactly one of 16 trials in the 6.25% block (approximately once
every two blocks), one of eight trials for the 12.5%-probability block, two of eight trials in the
25%-probability block, and four of eight trials in the 50%-probability block. Additionally,
forced-choice trials were presented quasi-randomly such that a given lever would be presented
on no more than two consecutive trials unless the other lever had already been presented eight
times in each block of forced-choice trials.
In each block, 16 forced-choice trials were followed by eight free-choice trials. Freechoice trials consisted of both levers extending into the chamber with a cue light illuminating
each. A response on either lever resulted in both levers being retracted, both cue lights being
extinguished, and delivery of the reinforcer associated with the lever upon which the response
occurred. A response on the lever associated with the small/certain reinforcer produced a single
pellet and a 0.1-s flash of the houselight, and a response on the lever associated with the
large/risky reinforcer produced four pellets and four flashes of the houselight, delivered with the
programmed probability. Unlike forced-choice trials, probabilities for the large/risky reinforcer
were independent for each trial, such that the probability of food-pellet delivery on a given trial
was not affected by the outcome of preceding trials. After food-pellet delivery, a 20-s ITI began.
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If no response was made within 10 s of the beginning of a forced- or free-choice trial (an
omission), the lever(s) would retract, cue lights would extinguish, and the 20-s ITI began.
Sessions terminated after 120 total trials (80 forced-choice and 40 free-choice), or 60 min
(including the 10-min blackout at the start of sessions), whichever occurred first.
Baseline
The baseline phase of the study consisted of a minimum of 20 sessions of probability
discounting, with stability observed for all rats after no more than 21 days. Baseline responding
was considered stable when the following criteria were met across five consecutive sessions: A
two-way analysis of variance (ANOVA) showed a main effect of block and neither a main effect
of session nor a session-by-block interaction, and visual inspection revealed no increasing or
decreasing trends in the total percentage of responses for the large/risky reinforcer, and a
minimum of 80% of responses (seven out of eight free-choice trials) for the large/risky reinforcer
in the first free-choice block (when both reinforcers were delivered with 100% probability).
Acute Chlordiazepoxide Administration
Once baseline responding reached stability, the same procedures used to establish
baseline probability-discounting functions were used to test effects of CDP and its vehicle
control (saline), with sessions conducted five days per week. CDP (1, 3, 10, 17, and 30 mg/kg) or
saline was administered to all rats on Tuesdays and Fridays to determine acute effects on
probability discounting and the relation between different doses and changes in risky choice
(dose-response function). Control sessions occurred on Mondays and Thursdays, with
Wednesday sessions being identical to control sessions.
Drug administration occurred only if the previous (control) day’s larger-reinforcer choice
in the first block was 80% or greater, and if the overall percent larger-reinforcer choices was
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within the range of the last five baseline sessions. For any test day on which drug-administration
criteria were not met, those sessions were identical to control sessions and testing did not resume
until drug-administration criteria were met. Vehicle was administered prior to drug
administration in order to allow for habituation to the injection procedure and to determine any
vehicle-induced effects on behavior.
Drug doses were administered in both ascending and descending sequences, with an
additional administration of vehicle occurring between each sequence. Each dose of CDP was
tested at least twice, with four rats starting with the highest dose and four rats starting with the
lowest dose. Additional doses were administered if high variability in larger-reinforcer choice
was observed on drug-administration days (see Table 1 for the number of administrations of each
dose in each phase). The 17.0 and 30.0 mg/kg doses were administered fewer times because of
increased omissions following initial administration of these doses (see Table 2 for the number
of omissions at each dose in each phase).
Chronic Chlordiazepoxide Exposure
Following acute drug administration, CDP was administered daily. The 10.0 mg/kg dose
was selected for chronic exposure because it was an intermediate dose that produced changes in
larger-reinforcer choice without producing excessive omissions during the acute phase.
Probability-discounting sessions were conducted seven days per week, with chronic CDP doses
administered 15 minutes prior to each session. Daily doses of 10.0 mg/kg CDP continued for a
minimum of 30 sessions (M = 56.4) and until choice was stable. Stability was determined using
the same criteria as the acute phase. Due to health issues that disrupted responding, responding
for one rat required 97 days to reach stability.
Chronic Dose-Response Determination
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Once responding was stable after at least thirty days of daily injections of 10.0 mg/kg
CDP, the dose-response function was re-determined using the same procedures as in the acute
phase of the study. Daily doses were administered at the same time of day as in the chronic
dosing phase, and all doses were administered to each rat 15 minutes prior to sessions. If drugadministration criteria were not met on control days, the 10.0 mg/kg dose was still administered
on test days (see “Acute chlordiazepoxide administration,” above). The same range of doses
were administered as in the acute phase to allow for comparisons of dose-response functions
from before and after chronic exposure.
Data Analysis
In general, data analysis consisted of four categories of comparisons. First, data from acute
test days were compared to determine how behavior changed following injections of either saline
or the range of CDP doses (i.e., acute dose-response function). Next, data from the first and last
five days of the chronic-exposure phase were used to compare how behavioral measures changed
as a function of chronic exposure to a single dose of CDP (10.0 mg/kg). Note that although this
phase is referred to as the chronic-exposure phase, chronic exposure continued into the final
phase of the study. In the final phase of the study, chronic injections of 10.0 mg/kg continued but
the full range of CDP doses were substituted on test days. Data from these test days were used to
compare changes in behavior following injections of either saline or the range of CDP doses in
the context of chronic exposure (i.e., chronic dose-response function). Finally, data from the
acute and chronic dose-response functions were compared to assess how CDP’s effects on
behavior changed as a function of chronic exposure.
Dependent measures
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Dependent variables included percent larger-reinforcer choice, indifference points (IPs),
area under the curve (AUC), win-stay ratios (WSRs), and lose-shift ratios (LSRs). Percent largerreinforcer choice was calculated block-by-block by dividing the number of free-choice trials in
which the larger reinforcer was selected by the total number of free-choice trials per block. A
session-by-session measure of percent larger-reinforcer choice was also calculated by dividing
the number of responses for the larger reinforcer during free-choice trials by the total number of
free-choice trials in a session. IPs were calculated by fitting a regression line to obtained data and
interpolating the probability at which choice for both reinforcers was equivalent.
To calculate AUC, probability of delivery was converted to “odds against delivery” by
determining the average number of unreinforced responses required before a reinforcer would be
delivered. For example, a 25% probability of delivery was converted to an odds-against value of
three because three unreinforced responses, on average, would occur before a reinforcer would
be delivered. Percent larger-reinforcer choice was plotted as a function of odds-against values
and vertical lines were drawn from each data point to the x-axis of the graph. Doing so created
four trapezoids under the discounting curve that were summed to determine the total area of the
graph beneath the curve. AUC was expressed as the proportion of the entire graph area
consumed by the trapezoids.
WSRs and LSRs were calculated by identifying whether a response was made for the
small/certain or large/risky reinforcer during free-choice trials, and whether the prior response
resulted in food-pellet delivery (a “win” or “loss”). Win-stay ratios consisted of the number of
responses for the large/risky reinforcer during free-choice trials that followed a “win” divided by
the total number of responses that resulted in a “win.” Essentially, WSRs were the proportion of
trials that followed a “win” on which responding stayed allocated toward the large/risky
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reinforcer. Lose-shift ratios consisted of the number of responses for the small/certain reinforcer
that followed a loss divided by the total number of responses that resulted in a “loss.”
Essentially, LSRs were the proportion of trials that followed a “loss” on which responding
shifted away from the large/risky reinforcer. Omission frequency was also recorded and analyzed
as a secondary dependent variable.
Acute Chlordiazepoxide Administration
Dose-response functions for percent larger-reinforcer choice, IP and AUC were determined
and visually analyzed. Overall percent larger-reinforcer choice and AUC were expected to
increase dose-dependently. Changes in these variables was assessed for statistical significance
with a series of repeated-measures analyses of variance (ANOVAs) and paired-samples t-tests.
Chronic Chlordiazepoxide Exposure
To assess changes in percent larger-reinforcer choice, IPs, AUC, WSRs, and LSRs as a
function of chronic drug exposure, data from the first and last five days of the chronic phase
were graphed for visual analysis. Statistical significance was assessed using repeated-measures
ANOVAS and paired-samples t-tests. Two rats died during the chronic-exposure phase of the
study. Therefore, all analyses of chronic drug effects and comparisons of acute and chronic
effects utilized a total of six rats.
Chronic Dose-Response Determination
The same measures used in the acute phase were assessed after chronic CDP exposure using
visual analysis, repeated-measures ANOVAs, and paired-samples t-tests. Acute and chronic
effects were also compared to one another using visual analysis, repeated-measures ANOVAs,
and paired-samples t-tests. Due to a global pandemic, laboratory facilities were closed prior to
the completion of the final dose-response determination. Complete data sets were collected for
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two rats, and partial data sets were collected for four rats. Missing data were excluded on an
analysis-by-analysis basis.
Results
Baseline
Figure 1 displays the mean percent larger-reinforcer choice for all rats (N = 8) during each
trial block under saline, 1.0, 3.0, and 10.0 mg/kg CDP. Note that data for the acute 17.0 and 30.0
mg/kg doses were omitted from all analyses because those doses disrupted magnitude
discrimination and increased trial omissions (see Table 1). Under saline, percent larger-reinforcer
choice decreased as a function of probability of delivery, indicating that responding was sensitive
to the programmed contingencies [F(2.04) = 123.40, p < .01].
Acute Percent Larger-Reinforcer Choice
Figures 1 and 2 show percent larger-reinforcer choice as a function of probability of
delivery for group and individual means, respectively. CDP increased percent larger-reinforcer
choice relative to saline [F(3) = 4.57, p = .01], particularly in the final three blocks, which
indicates increased risky choice. This effect was most pronounced at the 3.0 and 10.0 mg/kg
doses (see Figure 3). Pairwise comparisons indicated that 3.0 mg/kg CDP (M = 60.42, SE = 4.78,
p < .01) and 10.0 mg/kg CDP (M = 65.83, SE = 3.92, p = .02) significantly increased percent
larger-reinforcer choice relative to saline, although 1.0 mg/kg CDP also increased percent largerreinforcer choice in the third block.
A significant dose x block interaction was observed [F(3.49) = 2.58, p = .02], indicating that
CDP increased percent larger-reinforcer choice in some blocks more than others. To further
elucidate CDP’s effects on percent larger-reinforcer choice at the block-by-block level, a series
of paired-samples t-tests were conducted. Statistically significant increases in percent larger-
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reinforcer choice occurred primarily in the third block. At the 1.0 mg/kg dose, percent largerreinforcer choice was significantly higher in the third block, t(7) = 3.38, p = .01, relative to
saline. At the 3.0 mg/kg dose, percent larger-reinforcer choice was significantly higher in the
third block as well, t(7) = 4.13, p < .01. At the 10.0 mg/kg dose, larger-reinforcer choice was also
significantly higher in the third block, t(7) = 3.93, p < .01. An increase in larger-reinforcer choice
was also observed in the fourth block under 10.0 mg/kg CDP but was not statistically significant.
See Table 2 for means and SEM for percent larger-reinforcer choice during each block at each
dose.
AUC, IPs, WSRs, and LSRs
Figure 4 displays mean AUC under saline and each dose of CDP. CDP significantly
increased AUC relative to saline [F(3) = 3.61, p = .03], indicating increased risky choice. This
effect was most pronounced at the 3.0 and 10.0 mg/kg doses. A series of paired-samples t-tests
were conducted to examine changes in AUC at each dose of CDP relative to saline. AUC was
significantly higher under 3.0 mg/kg CDP [t(7) = 3.52, p = .01] and 10.0 mg/kg CDP [t(7) =
2.59, p = .04]. There was no statistically significant effect of dose on IPs, WSRs, or LSRs at any
dose of CDP. See Table 3 for means and SEM for AUC, IPs, WSRs, and LSRs at each dose of
CDP.
Omissions
Omissions occurred more frequently under CDP than saline during acute drug exposure
(see Table 1). This effect was most pronounced at the 17.0 and 30.0 mg/kg doses. A main effect
of dose was detected [F(5) = 35.30, p < .001], indicating that omissions occurred more often
following CDP administration. Post-hoc tests revealed that omissions occurred significantly
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more often at the 17.0 mg/kg (M = 25.13, SE = 15.48, p = .04) and 30.0 (M = 42.00, SE = 15.47,
p < .01) mg/kg doses relative to saline (M = 0.34, SE = 0.55).
Chronic CDP Exposure
Figure 5 displays mean percent larger-reinforcer choice during each block for the first and
last five days of the chronic-exposure phase, as well as under saline during baseline. Note that all
analyses after the initial acute-exposure phase were conducted with a total of six rats (N = 6).
Percent larger-reinforcer choice increased relative to saline during initial chronic exposure to
10.0 mg/kg CDP [F(2) = 4.41, p = .04] but subsided to near-baseline levels by the final five days
of chronic exposure. IPs, AUC, WSRs and LSRs were not significantly different from baseline at
either the beginning or the end of the chronic-exposure phase (see Figures 6-8). See Table 4 for
means and SEM for all dependent measures during the first and last five days of the chronicexposure phase, as well as under saline.
Chronic Percent-Larger Reinforcer Choice
Figure 9 shows percent larger-reinforcer choice as a function of probability of delivery at
each dose of CDP during chronic drug exposure. Note that the 17.0 and 30.0 mg/kg doses are
included in the figure, as once tolerance to CDP developed these doses no longer suppressed
responding after rats had been exposed to chronic CDP. CDP increased percent larger-reinforcer
choice relative to saline, F(5) = 11.37, p < .01, indicating an increase in risky choice. This effect
was most pronounced at the higher doses (10.0, 17.0, and 30.0 mg/kg). Pairwise comparisons
revealed a statistically significant effect of CDP relative to saline (M = 41.58, SE = 3.77) at the
10.0 (M = 59.75, SE = 2.54, p < .01), 17.0 (M = 57.00, SE = 3.46, p = .03), and 30.0 (M = 62.75,
SE = 4.50, p < .01) mg/kg doses. This effect was most pronounced in the third block (see Figures
9 and 10).
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A significant dose x block interaction was observed, F(20) = 4.25, p < .01, indicating that
CDP increased percent larger-reinforcer choice in some blocks more than others. To further
elucidate CDP’s effects on percent larger-reinforcer choice at the block-by-block level, a series
of paired-samples t-tests were conducted. At this level of analysis, percent larger-reinforcer
choice was significantly higher only at the 30.0 mg/kg, and only in the third block. Visual
analysis of Figures 9 and 10 suggests that 10.0 and 17.0 mg/kg also increased percent largerreinforcer choice in the third block.
Figure 10 shows mean percent larger-reinforcer choice as a function of probability of
delivery for individual rats during chronic drug exposure. CDP increased larger-reinforcer choice
for most rats, except for Rat 4. For Rat 4, larger-reinforcer choice was highest under saline and
decreased when CDP was administered. Larger-reinforcer choice under saline for Rat 4 was also
relatively higher than for other rats. This baseline-dependent pattern of responding was only
evident during chronic drug exposure, and only for the one rat.
Chronic AUC, IPs, WSRs, and LSRs
Figures 11 and 12 show AUC and IPs, respectively, as a function of drug dose. AUC was
higher under CDP relative to saline, indicating increased risky choice, but this increase was not
statistically significant. IPs were also higher at each dose of CDP relative to saline, indicating
increased risky choice. This effect was statistically significant [F(5) = 5.32, p < .01], and
pairwise comparisons revealed a statistically significant effect at the 30.0 mg/kg dose [t(4) =
3.52, p =.04]. There was no significant effect of CDP on WSRs or LSRs.
Chronic Omissions
During chronic exposure to 10.0 mg/kg CDP, higher doses of CDP (17.0 and 30.0 mg/kg)
did not significantly increase the number of omissions (see Table 1). In the context of chronic
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exposure, omissions were significantly more frequent under saline (M = 2.43, SE = 0.54, p = 0.1)
than 10.0 m/kg CDP (M = 0.15, SE = 0.15).
Acute vs Chronic Comparisons
Figure 13 shows percent larger-reinforcer choice as a function of probability of delivery for
saline during acute and chronic drug exposure. Percent larger-reinforcer choice under saline did
not change significantly as a function of chronic CDP exposure, indicating that risky choice
returned to baseline levels when chronic doses were replaced with saline. Figure 14 shows
percent larger-reinforcer choice as a function of drug dose during acute and chronic drug
exposure. Note that higher doses of CDP were required to reach the same levels of largerreinforcer choice seen during the acute phase (a rightward shift from the acute curve to the
chronic curve), but this effect was not statistically significant. Across doses, omissions were less
frequent during chronic drug exposure, F(1) = 23.85, p < .01 (see Table 1). CDPs effects on
AUC, IPs, WSRs and LSRs did not change significantly as a function of chronic exposure.
Discussion
The present study was designed to assess how CDP might affect risky choice in a
probability-discounting procedure. The procedure used in the present study was an effective tool
to assess changes in risky choice following acute and chronic administration of CDP. Under
baseline conditions, responding was sensitive to the programmed contingencies and largerreinforcer choice decreased as a function of probability of delivery. During acute drug exposure,
CDP dose-dependently increased larger-reinforcer choice, i.e., risky choice.
After chronic drug exposure, larger-reinforcer choice returned to baseline levels and
higher doses of CDP were required to increase larger-reinforcer choice, indicating tolerance to
CDP’s effects. The highest doses of CDP (17.0 and 30.0 mg/kg) produced excessive omissions
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in the acute phase but not after chronic drug exposure, providing further evidence for the
development of tolerance. The development of tolerance to CDP’s effects stands in accordance
with prior research on tolerance to certain effects of benzodiazepines (e.g., Bourin, 2019;
Gravielle, 2016; Johnson & Streltzer, 2013; McMillan & Leander, 1978; Potts & Krishnan,
1992; Rosenberg & Chiu, 1985; Sannerud et al., 1993). However, the results of the present study
are the first to demonstrate tolerance to CDP’s effects on risky choice.
Clinical Implications for Tolerance
Development of tolerance to CDP-induced increases in risky choice may be
advantageous from a clinical perspective. Acute exposure to CDP has been previously shown to
increase risky choice in several experimental paradigms and is associated with increases in a
variety of maladaptive behaviors (Daderman, 2005; Daderman & Edman, 2001; Daderman et al.,
2002; Deakin et al., 2004; Lane et al., 2005; 2008; Leung, 2011; Orriols et al., 2011; Pajunen et
al., 2017; Simoes et al., 2009, Van der Sluiszen et al., 2017). Results of the present study suggest
that increases in risky choice may not persist indefinitely, and that individuals prescribed CDP
for long periods of time may not continue to engage in increased risky choice. This could be
particularly beneficial given that there is little evidence that tolerance to the anxiolytic effects of
CDP develops in humans (for reviews, see Hood et al., 2012; Vinkers & Olivier, 2012).
Although the development of tolerance observed in the present study may be beneficial
from a clinical perspective, increases in risky choice prior to the development of tolerance would
not be. CDP increased risky choice during the acute-exposure phase and at higher doses after
chronic exposure. These findings add to the existing literature that CDP increases risky choice,
although the present findings are the first to demonstrate an increase in risky choice in a
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probability-discounting procedure and to show the development of tolerance to such effects
(Deakin et al., 2004; Lane et al., 2005; 2008).
GABA, Risky Choice and Schizophrenia
Because CDP is a GABA agonist, the present data support the notion that the GABA system
may be an important factor in risky choice. These results are in line with prior research that has
demonstrated that the GABA system is involved in risky choice (Bidwell et al., 2013; Murphy et
al., 2012; Paine, et al., 2011; Schindler, et al., 2014; Ucha et al., 2019). These results also
demonstrate that effects of CDP on risky choice are similar to those of ethanol, which also acts
on the GABA system (Wallin-Miller et al., 2017).
The GABA system may interact with risky choice in several ways. Disruption of GABA
receptors (reduced GABA transmission) in the prefrontal cortex of rats has been shown to
increase reward sensitivity but reduce risky choice (Piantadosi et al., 2016). While reward
sensitivity (as measured by WSRs) was not altered in the present study, benzodiazepines have
been shown to alter GABA activity in the prefrontal cortex and associated behavioral outcomes
(e.g., Dominguez et al., 2018; Lissek et al., 2017). GABA disruption in the prefrontal cortex has
also been associated with increased omissions in choice procedures and spatial discrimination
errors in radial-maze tasks (Auger & Floresco, 2014; Paine et al., 2011; 2015, Piantadosi &
Floresco, 2014). Such disruptions may explain why an increased number of omissions were
observed under saline during the chronic-exposure phase of the present study. That is, chronic
exposure to CDP likely resulted in decreased responsiveness of the GABA system, at which
point administration of saline instead of the chronic dose of CDP could have caused a deficit in
GABA signaling (e.g., Allison & Pratt, 2003; Bateson 2002).
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Disrupted GABA signaling may be related to some of the symptoms seen in psychiatric
disorders such as schizophrenia. Deficits in attention, working memory, impulse control,
discrimination of conditioned fear signals, cue salience, and decision-making are features of
impaired GABA functioning that share some similarities with symptoms of schizophrenia (e.g.,
Auger & Floresco, 2014; Kim et al., 2009; Lissek et al., 2017; Paine et al., 2011; 2015; Piandosi
& Floresco, 2014; Piandosi et al., 2016; Shurman et al., 2005). The results of the present study
provide further evidence that the GABA system may be an attractive target for research on
pharmacological treatments for symptoms of disorders such as schizophrenia.
Delay and Probability Discounting
The current study adds to the body of evidence that pharmacological manipulations can
produce differential results in delay- and probability-discounting procedures. Prior research on
benzodiazepines and delay discounting has been mixed. In one procedure, flunitrazepam
decreased delay discounting (decreased impulsive choice) in pigeons at all delay values
(Eppolito et al., 2011). In a study with Lewis and Fischer 344 with rats, low doses of diazepam
increased delay discounting while higher doses decreased delay discounting for Fischer 344 rats
but had no effect on Lewis rats (Huskinson & Anderson, 2012). On the other hand, diazepam has
not produced changes in measures of delay discounting in rhesus monkeys or humans (Maguire
et al., 2012; Reynolds et al., 2004). In contrast, CDP consistently and dose-dependently
increased larger-reinforcer choice in the present study.
Measurement
The present study employed several measures, some of which were selected because of their
utility in delay-discounting procedures. Percent larger-reinforcer choice, a direct measure of
responding, is based only on the assumption that changes in larger-reinforcer choice indicate
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changes in risky (or impulsive) choice. This assumption is accepted at all delay values in delay
discounting because it is always advantageous to choose the larger reinforcer, and choosing the
smaller reinforcer is always considered impulsive. In probability discounting, however, choosing
the larger reinforcer is advantageous only when the probability of delivery is relatively high.
Thus, increases in larger-reinforcer choice are only said to reflect increased risky choice when
the odds of delivery are relatively low. Therefore, measures based on whole-session responding
(high- and low-probability trials) may not reflect risky choice as accurately as block-by-block
measures.
Whole-Session Measures
AUC and IPs appeared to be less sensitive than percent larger-reinforcer choice as
measures of risky choice. Although AUC and IPs are derived from larger-reinforcer choice, they
are calculated using whole-session responding rather than block-by-block responding. Changes
in larger-reinforcer choice that occurred at lower probabilities (i.e., the third, fourth, and fifth
blocks) may not have been large enough to significantly increase AUC and IPs in most cases.
While these measures are commonly used in delay-discounting studies, they may not be
appropriate for analyzing probability-discounting data.
AUC and IPs should be interpreted with caution for several reasons. In the present study,
changes in responding in the first two blocks do not indicate changes in risky choice yet are
factored into the calculation of AUC and IPs. Additionally, larger-reinforcer choice in the first
two blocks was often at or near 100%. Thus, increases in larger-reinforcer choice in later blocks,
while significant on their own, may not have been large enough to produce a significant change
in overall AUC or IPs.
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Although AUC and IPs may not adequately characterize risky choice in probabilitydiscounting procedures, these measures do have one advantage over percent larger-reinforcer
choice. AUC and IPs take into account the relative differences in probability of delivery for each
block. For example, the portions of the graph that are summed to calculate AUC become larger
as the odds against delivery become greater (as probability of delivery decreases). This means
that an increase in larger-reinforcer choice in the final block would increase the overall AUC
more than an identical increase in larger-reinforcer choice in the first block. Similarly, the
regression line that is fitted to raw data and used to interpolate IPs weights changes in largerreinforce choice more heavily as the odds against delivery increase.
Block-by-Block Measures
Block-by-block measures of risky choice (i.e., larger-reinforcer choice) were most
sensitive to CDP’s effects, but did not take into account changes in the risk associated with
larger-reinforcer choice across blocks. Changes in larger-reinforcer choice were most evident in
the third trial block, with clear increases also observed in the fourth, and to a lesser extent, fifth
blocks. In the third block, the probability of delivery was 25%. Over repeated trials, this response
option would yield an average of 0.75 pellets/response (compared to 1.0 pellet/response for the
small/certain option across all blocks). The difference in average yield between the two response
options was smallest in the third block with a difference of 0.25 pellets/response. As the
difference in average yield between the response options increased across blocks, CDP’s effect
on larger-reinforcer choice became smaller and smaller. This suggests that as the discriminability
of the two contingencies in each block increased, larger-reinforcer choice was less sensitive to
CDP’s effects.
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In the fifth block, with a very low probability of reinforcer delivery and an average
larger-reinforcer yield of only 0.19 pellets/response, responding for the large/risky reinforcer was
rarely reinforced. Considering the low rates of responding and the equally low probability of
reinforcement in this block, increases in percent larger-reinforcer choice may carry more
theoretical weight (i.e., be considered riskier) than in other blocks with higher rates of
reinforcement (Yates, 2019). That is, it is possible that the disparity in average larger-reinforcer
yield became more and more discriminable as the probability of reinforcer delivery decreased
across blocks. Therefore, increases in larger-reinforcer choice during the final block may reflect
a stronger effect than a similar increase in prior blocks.
Individual Differences
Behavior analysis is rooted in single-subject experimental designs, yet discounting research
often employs group designs (Sidman, 1988). In the present study, larger-reinforcer choice for
Rat 1 was increased to nearly 100% by the 10.0 mg/kg acute dose across all blocks. This extreme
increase in later blocks was not evident in any other doses or rats. This pattern continued during
the chronic phase to a lesser extent, with larger-reinforcer choice for Rat 1 consistently higher
than for any other rats in the third block. It is unclear what may have caused this individual
difference in responding.
A baseline-dependent effect appears to have occurred for one rat during chronic exposure.
Larger-reinforcer choice for Rat 4 was consistently higher than for all other rats under saline, and
contrary to its effect on responding for all other rats, larger-reinforcer choice was decreased
following CDP administration. It is worth noting that during the chronic phase of this
experiment, rats had been receiving daily doses of 10.0 mg/kg CDP for at least 50 days.
Therefore, increases in larger-reinforcer choice relative to 10.0 mg/kg are a more relevant
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indicator of CDP’s effects. Nonetheless, for all other rats, larger-reinforcer choice was decreased
by saline administration and decreased by CDP administration in the chronic phase.
Limitations and Future Directions
There were several limitations to the present study. During the acute-exposure phase, each
rat received each dose of CDP at least twice. However, due to unforeseen emergent
circumstances, data collection was concluded before the same number of data points could be
acquired for each dose after chronic drug exposure. Furthermore, two rats died at the beginning
of the chronic-exposure phase, leaving the total number of rats available for cross-phase
comparisons at six. Undoubtedly, the reduced number of data points and the overall reduced
sample size reduced the statistical power of all analyses conducted after the acute phase. This
lack of power may have contributed to the apparent lack of significant effects of CDP on some
measures, such as AUC and IPs. Despite these limitations, the present study provides evidence
that CDP increases risky choice, and that tolerance to this effect develops over time.
Another limitation to the present study was that all the rats used as subjects were male. Prior
research has demonstrated sex-specific differences in baseline decision making, as well as sexdependent drug effects. Ethanol, a GABA agonist, has been shown to increase risky choice in
male rats, but not females (Wallin-Miller et al., 2017). Interestingly, a separate study
demonstrated that testosterone may alter risky choice in males by increasing loss aversion and
decreasing reward sensitivity (Wallin-Miller et al., 2015). Taken together, these findings indicate
that there may be significant sex-specific differences in risky choice both before and after
exposure to GABA agonists. Such differences limit the generality of the present study’s findings.
Future research should consider how different manipulations of probability and reinforcer
magnitude affect risky choice. The present study used one- and three-pellet reinforcer
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magnitudes for the small/certain and large/risky response options, respectively. Prior studies
have used a variety of reinforcer magnitudes, with varying discrepancies between the
small/certain and large/risky options (e.g., Bidwell et al., 2013; St. Onge et al., 2010; Yates,
2019). It is unknown how changes in reinforcer discrepancy affect risky choice. Similarly, the
present study used a range of probabilities that differed from previous research. Prior studies
have employed several various ranges of probabilities (e.g., 100/66/33/16.5%, 100/50/25/0%),
often in combination with larger-reinforcer magnitudes that result in only the block with the
lowest probability providing a risky choice (i.e., a choice involving a large/risky response option
with a lower average yield than the small/certain option). The present study included three
blocks with probabilities in which, given the three-pellet reinforcer magnitude, larger-reinforcer
choice was considered risky. Further research should elucidate how different combinations of
reinforcer magnitude and probability of delivery affect risky choice.
In the present study, larger-reinforcer choice was optimal (not risky) in the first two blocks.
While the first (100%) block served the purpose of ensuring that responding discriminated
between the larger and smaller reinforcers when probability of delivery was equal, the second
(50%) block served no such purpose. Future research should assess the effects and utility of
including multiple probabilities at which choice for the larger reinforcer is optimal. It is possible
that including multiple blocks without risky options could affect responding in later blocks with
riskier response options. In either case, including more than a single block with a high
probability of reinforcer delivery may not be necessary.
Because the relative riskiness of larger-reinforcer choice changes with different
probabilities of delivery, a measure that accounts for relative risk but excludes responding at
high probabilities of delivery could prove useful. Probability-discounting procedures represent a
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relatively new behavioral paradigm that is distinct from delay discounting. While some of the
structural features of delay-discounting procedures have been useful in developing probabilitydiscounting procedures, measures and methods of data analysis unique to probability discounting
are needed (e.g., Green & Myerson, 2019; Yates, 2019). Still, modern probability-discounting
research has yet to employ novel measures of probability discounting (e.g., Islas-Preciado et al.,
2020; Ozga & Anderson, 2019; Yates et al., 2019).
A novel measure for probability discounting would need to address several issues. First, an
improved measure of probability discounting should weight greater amounts of risk (i.e., lower
probabilities of delivery) more heavily than lesser amounts of risk. Secondly, such a measure
should exclude any trial blocks in which the expected value of the larger reinforcer is equal to or
greater than that of the smaller reinforcer. For example, an economist might define risk as the
difference between optimal and obtained outcomes in a choice scenario (Keeney & Raiffa,
1993).
In the present study, risk could be conceptualized as the difference in average yields
between the smaller and larger reinforcer at a given probability. A response for the smaller
reinforcer in the third block has an average yield of 1.0 pellets/response. A response for the
larger reinforcer in the third block has an average yield of 0.75 pellets/response, so the risk
associated with larger-reinforcer choice in the third block is (1.0 – 0.75) 0.25. Probability of
delivery is four times smaller in the fifth block, so the risk is accordingly higher as well at
0.8125. These measures of risk could then be used to weight a measure such as larger-reinforcer
choice in statistical analyses. While this measure would need to be adjusted to account for actual
obtained number of reinforcers and suboptimal responding in baseline, it meets the requirements
described above and lends itself well to statistical analysis.
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.
Although the present study adds to the body of evidence that implicates the GABA system
in risky choice, changes in GABA were not directly measured. To further clarify the relation
between benzodiazepines, GABA, and risky choice, GABA receptors could be further
manipulated. For example, a drug that prevents CDP from increasing GABA activity (a GABA
antagonist) could be administered. Bicuculline is one such antagonist (for a review of GABA
antagonists, see Johnston, 2013). Comparisons of risky choice after exposure to CDP in
combination with bicuculline and exposure to CDP alone could help elucidate effects of CDP
and the role of GABA in risky choice. This line of inquiry could be further pursued by
investigating effects of specific subunits of GABA receptors. Although the GABAA subtype is
thought to be the primary contributor to changes in anxiety and risky choice, GABAA receptors
can further be divided into six subunits.
Some subunits of the GABAA receptor are differentially associated with specific
benzodiazepine effects (for a review, see Sigel & Steinmann, 2012). The α1 subunit is involved
in sedation and amnesia, while α2 and α3 are involved in anxiolysis. The α5 subunit is associated
with benzodiazepine-related impairments in learning and memory. It is therefore possible that
one or more subunits is differentially involved in risky choice. Pharmacological manipulation of
specific subunits could help to pinpoint with greater specificity the mechanism by which CDP
and GABA affect risky choice (e.g., Fischer, 2011; Jansen et al., 2008; Schwienteck et al., 2017).
Such knowledge could also aid in determining the mechanisms by which differential tolerance to
the therapeutic and iatrogenic effects of CDP develops.
Future research on probability-discounting and CDP should also investigate the possibility
of baseline-dependent effects. A baseline-dependent effect was observed for a single rat during
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one phase of the present study. Because baseline risky choice was otherwise relatively
homogeneous, it is unclear if this effect would have been more pronounced in a sample with
varying levels of baseline risky choice. This could be accomplished by assigning animals to
experimental conditions based on their natural baseline behavior or by artificially inducing
different baseline behavior through procedural manipulations. A third possibility would be to
compare CDP’s effects on different strains of rats with different baseline levels of risky choice
(e.g., Huskinson et al., 2012, Ozga & Anderson, 2018).
Summary and Conclusions
As a result of incomplete data collection and reduced statistical power in the present study,
some of the results should be interpreted with caution. However, there are at least two
conclusions that can be drawn with relative confidence regarding effects of CDP on risky choice:
acute administration of CDP dose-dependently increased larger-reinforcer choice and chronic
exposure to CDP resulted in tolerance to those effects. Furthermore, no changes in WSRs or
LSRs were observed at any dose of CDP. Therefore, it is unlikely that increases in largerreinforcer choice were driven by changes in reinforcer sensitivity or loss sensitivity.
The results of the present study indicate that further research is necessary to better
understand how CDP and other benzodiazepines affect complex behavior. While CDP did
increase larger-reinforcer choice, choosing between smaller/certain outcomes and large/risky
outcomes is a necessary but not sufficient feature of risky choice in humans (e.g., Green &
Myerson, 2019). Furthermore, whole-session measures of choice such as AUC and IPs should be
used with caution as measures risky choice. Although increased risky choice is not a listed sideeffect of benzodiazepines, the present study adds to the body of research indicating that
benzodiazepines can increase risky choice (e.g., Ahwazi & Abdijadid, 2019). The results of the
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present study are novel in that they demonstrate that CDP increases risky choice in a probabilitydiscounting procedure, and importantly that tolerance to this effect develops over time.
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Table 1
Mean and SEM for omitted trials at each dose of CDP in each phase.
Dose CDP (mg/kg)
Saline

1.0

3.0

10.0

17.0

30.0

Phase

M

SEM

M

SEM

M

SEM

M

SEM

M

SEM

M

SEM

Acute

0.34

0.18

0.38

0.15

0.19

0.11

0.85

0.51

25.13

4.73

42.00

5.82

Chronic

2.43

0.75

6.04

2.58

1.29

0.49

0.15

0.15

2.67

1.30

0.10

0.10

N=8
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Table 2
Mean and SEM for acute percent larger-reinforcer choice in each block during acute drug
exposure.
Dose CDP (mg/kg)
Saline

1.0

3.0

10.0

Block

M

SEM

M

SEM

M

SEM

M

SEM

1

99.48

0.52

100.0

0.00

97.92

1.04

98.44

1.02

2

85.05

5.14

89.32

5.06

94.01

3.42

90.23

2.73

3

33.67

6.91

61.20

12.18

71.61

8.09

72.92

8.22

4

11.33

7.48

19.80

7.03

22.96

9.89

39.97

9.64

5

7.63

3.23

5.21

3.82

14.58

8.55

24.61

11.02

N=8
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Table 3
Mean and SEM for area-under-the-curve (AUC), indifference points (IPs), win:stay ratios
(WSRs) and lose:shift ratios (LSRs) during acute drug exposure.
Dose CDP (mg/kg)
Saline

1.0

3.0

10.0

M

SEM

M

SEM

M

SEM

M

SEM

AUC

.24

.04

.31

.05

.38

.07

.46

.07

IPs

2.55

0.63

4.02

0.82

7.08

2.60

4.86

0.66

WSRs

.65

.02

.63

.02

.63

.03

.60

.03

LSRs

.90

.03

.93

.04

.91

.04

.87

.04

N=8
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Table 4
Mean and SEM for percent larger-reinforcer choice (% LRC), area-under-the-curve (AUC),
indifference points (IPs), win:stay ratios (WSRs) and lose:shift ratios (LSRs) during the first and
last five days of chronic exposure.
Condition
Saline

First Five

Last Five

Measure

M

SEM

M

SEM

M

SEM

% LRC

45.47

2.33

68.65

5.58

55.97

6.13

AUC

.23

.04

.34

.08

.27

.06

IPs

2.55

0.63

4.76

1.78

3.24

0.91

WSRs

.65

.18

.61

.02

.61

.01

LSRs

.90

.03

.89

.06

.92

.04

N=6
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Table 5
Mean and SEM for percent larger-reinforcer choice in each block at each dose of CDP during
chronic drug exposure.
Dose CDP (mg/kg)
Saline

1.0

3.0

Block

M

SEM

M

1

100.00

0.00

98.96

1.04 98.96

2

80.90

10.13 83.33

3

34.03

4
5
N=6

SEM

M

10.0

SEM

M

17.0

30.0

SEM

M

SEM

M

SEM

1.04 100.00

0.00

98.96

1.04

100.00

0.00

7.85 92.71

6.13

97.92

1.32

97.92

1.32

96.25

2.50

12.52 17.71

6.13 41.67

7.16

67.71

12.22 66.67

9.08

82.50

9.35

12.50

7.76

2.08

1.32

8.33

4.47

9.38

5.98

15.63 10.92

20.00

13.02

2.08

1.42

1.04

1.04

4.17

2.64

9.38

4.19

2.08

15.00

7.29

2.08
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Table 6
Mean and SEM for area under the curve (AUC), indifference points (IPs), win:stay ratios
(WSRs), and lose:shift ratios (LSRs) at each dose of CDP during chronic drug exposure.
Dose CDP (mg/kg)
Saline

1.0

3.0

10.0

17.0

30.0

Measure

M

SEM

M

SEM

M

SEM

M

SEM

M

SEM

M

SEM

AUC

.22

.06

.13

.02

.24

.03

.30

.04

.31

.05

.31

.06

IPs

2.37

0.82

1.53

0.22

2.54

0.47

3.78

0.60

3.96

.86

5.95

1.73

WSRs

.59

.01

.65

.02

.6.

.04

.54

.04

.57

.03

.62

.06

LSRs

.91

.04

.76

.06

.85

.09

.84

.05

.87

.09

.87

.10

N=6
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Figure 1
Group means and SEM for percent larger-reinforcer choice as a function of probability of
delivery during acute drug exposure.

% Larger-Reinforcer Choice

Group Means - Acute
100

SAL
1.0 mg/kg CDP

80

3.0 mg/kg CDP

60

10.0 mg/kg CDP

40
20
0

N=8
100%

50%

25%

12.5%

6.25%

Probability of Delivery
Note. Percent larger-reinforcer choice in the third (25%) block was significantly higher for 1.0 (p
= .01), 3.0 (p < .01), and 10.0 (p < .01) mg/kg CDP relative to saline. The acute 17.0 and 30.0
mg/kg doses were excluded from analysis due to generalized response disruption.
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Figure 2
Individual means and SEM for percent larger-reinforcer choice as a function of probability of
delivery during acute drug exposure.
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Figure 3
Means and SEM for overall (full session) percent larger-reinforcer choice as a function of dose
during acute drug exposure.

100
80
60
40
20

N=8
.0
10

3.

0

0
SA
L
1.
0

% Larger-Reinforcer Choice

Acute Dose-Response Function

CDP Dose (mg/kg)
Note. Overall percent larger-reinforcer choice was significantly higher relative to saline under
3.0 (p < .01) and 10.0 (p = .02) mg/kg CDP.
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Figure 4
Means and SEM for area under the curve as a function of dose during acute drug exposure.

Acute Dose-Response Function
Area Under the Curve

1.0
0.8
0.6
0.4
0.2

N=8
.0
10

0
3.

SA
L
1.
0

0.0

CDP Dose (mg/kg)
Note. Area under the curve was significantly higher relative to saline at 3.0 (p = .01) and 10.0 (p
= .04) mg/kg CDP.
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Figure 5
Mean and SEM for percent larger-reinforcer choice as a function of probability of delivery for
acute saline, first five days of initial chronic drug exposure, and last five days of initial chronic
drug exposure.

% Larger-Reinforcer Choice

Larger Reinforcer Choice
100

Saline
First Five Days

75

Last Five Days

50
25
0

N=6
100%

50%

25%

12.5%

6.25%

Probability of Delivery
Note. Percent larger-reinforcer choice was significantly higher than saline during the first five
days of chronic drug exposure (p = .04), but not the last five days.
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Figure 6
Mean and SEM for indifference points during the first and last five days of chronic drug
exposure, as well as for baseline saline.

Indifference Points
Odds Against Delivery

8
6

N=6

4
2
0

Saline
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Figure 7
Means and SEM for area under the curve during the first and last five days of chronic drug
exposure, as well as for baseline saline.

Proportion of Total Area

Area Under the Curve
0.5
0.4

N=6

0.3
0.2
0.1
0.0

Saline

First Five
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Figure 8
Means and SEM for win:stay ratios and lose:shift ratios during the first and last five days of
chronic drug exposure, as well as for baseline saline.
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Figure 9
Group means and SEM for percent larger-reinforcer choice as a function of probability of
delivery during chronic drug exposure.

% Larger-Reinforcer Choice

Group Means - Chronic
100

SAL

80

1.0 CDP
3.0 CDP

60

10.0 CDP
17.0 CDP

40
20
0

30.0 CDP
N=6
100%

50%

25%

12.5%

6.25%

Probability of Delivery
Note. Percent larger-reinforcer choice was higher in the third (25%) block relative to saline at the
10.0 (p < .01), 17.0 (p = .03), and 30.0 (p < .01) mg/kg doses of CDP.
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Figure 10
Means and SEM for percent larger-reinforcer choice as a function of probability of delivery for
individual rats during chronic drug exposure.
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Figure 11
Means and SEM for area under the curve as a function of dose during chronic drug exposure.
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Figure 12
Means and SEM for indifference points as a function of dose during chronic drug exposure.
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2
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L
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0
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Note. Indifference points were higher relative to saline at the 30.0 mg/kg dose of CDP (p = .04).
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Figure 13
Means and SEM for percent larger-reinforcer choice under saline during acute and chronic
drug exposure.
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Figure 14
Means and SEM for overall (full session) percent larger-reinforcer choice as a function of dose
during acute and chronic drug exposure.

100

Acute
Chronic

80
60
40

.0
30

.0
17

.0

0

N=6
10

20

SA
L
1.
0
3.
0

% Larger-Reinforcer Choice

Dose-Response Function
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Note. The 17.0 and 30.0 mg/kg doses from the acute-exposure phase were excluded from
analysis due to generalized response disruption.

